Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.31	$1.73	$1.11 ▼ $5.00	$614.78M	1.75	1.57 million shs	2.09 million shs
ERYP ERYTECH Pharma	$3.10	$4.66	$0.30 ▼ $1.47	$105.77M	2.69	93,510 shs	N/A
RGNX REGENXBIO	$8.39 -4.1%	$8.97	$5.04 ▼ $20.00	$420.84M	1.09	922,893 shs	1.19 million shs
SANA Sana Biotechnology	$2.81 -2.1%	$2.19	$1.26 ▼ $7.40	$633.60M	1.78	3.66 million shs	5.96 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	+12.68%	+32.76%	+49.03%	-33.62%
ERYP ERYTECH Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
RGNX REGENXBIO	0.00%	-0.47%	-3.34%	+17.34%	-28.29%
SANA Sana Biotechnology	0.00%	+7.66%	+30.09%	+67.26%	-48.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.8443 of 5 stars	3.5	1.0	0.0	0.0	3.1	3.3	0.6
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	4.5348 of 5 stars	3.4	3.0	0.0	4.6	2.7	3.3	0.6
SANA Sana Biotechnology	2.7337 of 5 stars	3.5	1.0	0.0	0.0	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	303.46% Upside
ERYP ERYTECH Pharma	0.00	N/A	N/A	N/A
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	276.94% Upside
SANA Sana Biotechnology	3.00	Buy	$8.60	206.05% Upside

Current Analyst Ratings Breakdown

Latest ERYP, AUTL, SANA, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	AUTL Autolus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	60.75	N/A	N/A	$1.61 per share	1.43
ERYP ERYTECH Pharma	$32.66M	3.24	N/A	N/A	$0.80 per share	3.88
RGNX REGENXBIO	$156.72M	2.69	N/A	N/A	$5.24 per share	1.60
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
ERYP ERYTECH Pharma	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)

Latest ERYP, AUTL, SANA, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
ERYP ERYTECH Pharma	0.32	3.65	3.65
RGNX REGENXBIO	N/A	2.93	2.93
SANA Sana Biotechnology	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
ERYP ERYTECH Pharma	1.09%
RGNX REGENXBIO	88.08%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
ERYP ERYTECH Pharma	1.94%
RGNX REGENXBIO	12.79%
SANA Sana Biotechnology	31.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
ERYP ERYTECH Pharma	49	34.12 million	33.46 million	Not Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable
SANA Sana Biotechnology	380	225.48 million	155.35 million	Optionable

ERYP, AUTL, SANA, and RGNX Headlines

Recent News About These Companies

Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results

June 29 at 4:08 AM | insidermonkey.com

Sana Biotechnology’s SWOT analysis: promising cell therapy stock faces crowded market - Investing.com

June 26, 2025 | investing.com

Sana Biotechnology (SANA) Receives a Buy from Citizens JMP

June 26, 2025 | theglobeandmail.com

Sana Biotechnology (NASDAQ:SANA) Earns Market Outperform Rating from JMP Securities

June 26, 2025 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 4.5% - Time to Sell?

June 25, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $10.80 Consensus Price Target from Brokerages

June 25, 2025 | americanbankingnews.com

BofA Remains Bullish on Sana Biotechnology (SANA)

June 24, 2025 | insidermonkey.com

Sana Biotechnology (NASDAQ:SANA) Given Market Outperform Rating at JMP Securities

June 24, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 17.2% - Should You Buy?

June 23, 2025 | marketbeat.com

Sana Biotechnology stock soars after positive diabetes treatment results

June 23, 2025 | investing.com

Two Biotech Stocks Poised For Big Moves On Monday

June 23, 2025 | benzinga.com

Sana Biotechnology Shares Climb on Positive Diabetes Study Results

June 23, 2025 | marketwatch.com

Sana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 Diabetes

June 23, 2025 | quiverquant.comQ

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

June 23, 2025 | globenewswire.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from Analysts

June 22, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Acquired by Clarius Group LLC

June 20, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.3% - Still a Buy?

June 17, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's Why

June 11, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 8.3% - What's Next?

June 10, 2025 | marketbeat.com

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

June 9, 2025 | globenewswire.com

Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP, AUTL, SANA, and RGNX Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.31 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.36 +0.05 (+2.16%)

As of 04:50 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

REGENXBIO NASDAQ:RGNX

$8.39 -0.36 (-4.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$20.00 +11.61 (+138.38%)

As of 04:00 AM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Sana Biotechnology NASDAQ:SANA

$2.81 -0.06 (-2.09%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.84 +0.03 (+1.03%)

As of 05:04 AM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time